Table 3.
Multivariable Cox regression analyses predicting the risk of overall recurrence, CSM and OM in patients treated with RNU after propensity matching 1:1
| Variables | Overall recurrence |
CSM |
OM |
|||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Age, years | 1.00 (0.99–1.02) | 0.5 | 1.03 (1.01–1.05) | 0.004 | 1.04 (1.02–1.06) | <0.001 |
| Gender (male vs female) | 0.82 (0.60–1.12) | 0.2 | 0.81 (0.54–1.21) | 0.3 | 0.73 (0.51–1.05) | 0.09 |
| LRNU vs ORNU | 1.33 (0.96–1.84) | 0.08 | 0.69 (0.43–1.11) | 0.1 | 1.01 (0.68–1.50) | 0.9 |
| pT stage pT2 vs pT1-0 pT3–4 vs pT1–0 |
1.75 (1.13–2.72) 3.44 (2.17–5.45) |
0.01 <0.001 |
1.70 (0.80–3.59) 5.67 (2.74–11.75) |
0.1 <0.001 |
0.77 (0.46–1.32) 1.66 (0.96–2.88) |
0.3 0.07 |
| Presence of LNI | 2.30 (1.48–3.56) | <0.001 | 2.59 (1.60–4.18) | <0.001 | 2.49 (1.55–3.97) | <0.001 |
| Number of LN removed | 1.01 (0.99–1.03) | 0.06 | 1.01 (0.99–1.04) | 0.1 | 1.01 (0.99–1.03) | 0.3 |
| Presence of LVI | 1.52 (1.10–2.12) | 0.01 | 1.26 (0.81–1.96) | 0.3 | 1.35 (0.91–2.02) | 0.1 |
| Pathologic grade (HG vs LG) | 0.32 (0.23–0.45) | <0.001 | 0.88 (0.55–1.41) | 0.6 | 1.53 (0.99–2.35) | 0.05 |
| Tumour necrosis | 1.38 (1.01–1.92) | 0.04 | 1.30 (0.86–1.95) | 0.2 | 1.21 (0.83–1.76) | 0.3 |
| Presence of concomitant CIS | 1.01 (0.74–1.40) | 0.9 | 0.93 (0.61–1.42) | 0.7 | 0.92 (0.63–1.34) | 0.6 |
| Presence of PSM | 0.69 (0.35–1.36) | 0.3 | 1.16 (0.53–2.57) | 0.7 | 1.08 (0.43–2.70) | 0.8 |
| Adjuvant chemotherapy | 0.82 (0.54–1.25) | 0.4 | 1.27 (0.79–2.03) | 0.3 | 0.91 (0.56–1.47) | 0.7 |
HG, high grade; LG, low grade; PSM, positive surgical margins.